Form 4: Vir Biotechnology CFO Jason O'Byrne Acquires Shares and Stock Options
SEC Form 4 Filing
Vir Biotechnology's Chief Financial Officer, Jason O'Byrne, acquired 75,000 shares of common stock and 150,000 stock options on November 15, 2024.
Summary
- Jason O'Byrne, the EVP & Chief Financial Officer of Vir Biotechnology, acquired 75,000 shares of common stock on November 15, 2024.
- These shares were acquired at a price of $0, indicating they were likely restricted stock units.
- O'Byrne also acquired 150,000 stock options with an exercise price of $8.64 on the same date.
- The stock options vest over time, with 25% becoming exercisable on November 15, 2025, and the remainder vesting monthly over the following 36 months.
- The stock options expire on November 14, 2034.
Sentiment
Score: 6
Explanation: The document is a routine filing related to executive compensation. It is neither particularly positive nor negative, but indicates standard practice.
Positives
- The acquisition of shares and stock options by the CFO could be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of compensation for executives in the biotechnology industry.
- The vesting schedule of the stock options is typical, with a portion vesting after one year and the remainder vesting over the following years.
- The exercise price of the stock options is likely based on the company's stock price at the time of the grant.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment, as it indicates the CFO's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 11/15/2024 | Date of acquisition of 75,000 common stock shares and 150,000 stock options. |
| 11/15/2025 | 25% of the stock options become exercisable. |
| 11/14/2034 | Expiration date of the stock options. |
| 11/18/2024 | Date the Form 4 was signed. |
Keywords
Vir Biotechnology, Jason O'Byrne, stock options, restricted stock units, insider trading, equity incentive plan, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.